[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-cell-lung-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,40,73,104,153,180,253,276,301,324,350,380,406,427,457,487,509,529,555,576,594,627,651,677,705],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053514","tracking-thoracic-cancer-evolution-through-therapy-rx-evo-100053514",false,"NCT05628376","TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO","Inclusion Criteria:\n\n* Cohort A, B and C :\n\n  * Written Informed consent\n  * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.\n  * Agreement to be followed up at a TRACERx EVO site\n\nCohort A:\n\n* Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery\n* Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)\n* Primary surgery in keeping with NICE guidelines (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)\n* For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter of at least 15mm on imaging to allow for tissue sampling of at least two tumour regions; this can either be two fresh tissue samples or one fresh tissue sample plus one representative diagnostic FFPE block (to be requested at a later date according to trial specific procedures)\n* Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.\n* Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated\n* Performance status 0 to 2\n\nCohort B:\n\n* Participants ≥18 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2 Participants who were initially consented into Cohort A who are found to have more advanced disease pre- or immediately post operatively (e.g. locally advanced\u002Finoperable or stage IV disease) could be included in Cohort B.\n\nCohort C:\n\n* Participants ≥18 years of age, with any stage SCLC or pleural mesothelioma.\n* Sufficient tissue (at least 1 region\u002Fbiopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2\n\nExclusion Criteria:\n\n* Cohort A, B and C:\n\n  * Any other active or current malignancy and\u002For systemic treatment (excluding hormone therapy) for that malignancy in the last 12 months (i.e., participant must be cancer free for the last 12 months, and if on therapy it can only be hormone therapy).\n\n    * Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer, or for Cohort C, cases of NSCLC that have transformed to SCLC, or for Cohort A another synchronous lung cancer.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated severe co-morbid conditions\n\nCohort A:\n\n* Positive margins, incomplete resection or insufficient nodal sampling\n* Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging, or for participants having neoadjuvant therapy at least one tissue biopsy unable to be obtained prior to neoadjuvant therapy (Fresh Frozen or FFPE).\n* Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B\u002FC:\n\n• Insufficient tissue, i.e., at least one tissue biopsy unable to be obtained (Fresh Frozen or FFPE)","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.",[24,25,26],"Lung Cancer, Non-small Cell","Small Cell Lung Cancer","Pleural Mesothelioma","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2023-10-20",{"date":35,"type":20},"2034-06",{"name":37,"class":38},"University College, London","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100604873","phase-2-a-study-to-evaluate-the-optimal-dose-adverse-events-and-change-in-disease-activity-of-intravenous-abbv-706-in-combination-with-atezolizumab-versus-standard-of-care-as-first-line-treatment-in-adult-participants-with-previously-untreated-extensive-stage-small-cell-lung-cancer-100604873","NCT07155174","A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","SEZanne","Inclusion Criteria:\n\n* Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.\n* Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* Suspected brain metastases at screening should have a computed tomography (CT)\u002F magnetic resonance imaging (MRI) of the brain prior to study entry.\n\nExclusion Criteria:\n\n* Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).\n* Known active\u002Fsymptomatic central nervous system (CNS) metastases should be excluded.\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD\u002Fpneumonitis on screening chest computed tomography (CT) scan should be excluded.\n* Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.",{"count":49,"type":20},180,"INTERVENTIONAL",[52],"PHASE2","Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).\n\nABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.\n\nIn the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.",[25],[25,56,57,58,59,60,61],"SCLC","ABBV-706","Etoposide","Carboplatin","Atezolizumab","Lurbinectedin","2026-06-30",{"date":64,"type":31},"2026-07-02",{"date":66,"type":31},"2025-11-25",{"date":68,"type":20},"2031-09",{"name":70,"class":71},"AbbVie","INDUSTRY",57,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":39},"100220369","tissue-procurement-and-natural-history-study-of-people-with-non-small-cell-lung-cancer-small-cell-lung-cancer-extrapulmonary-small-cell-cancer-pulmonary-neuroendocrine-tumors-and-thymic-epithelial-tumors-100220369","NCT02146170","Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","* INCLUSION CRITERIA:\n* Individuals with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET.\n* Individuals consulted in the Clinical Center without a definitive diagnosis, but clinically considered likely to have a malignancy of the above histologies, pending further tissue acquisition and\u002For pathology review.\n* Age greater than or equal to18 years. Children are excluded from the study, as the above thoracic malignancies are rare in this population.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject, at the discretion of the Principal Investigator.\n* Known HIV-positive individuals not on combination antiretroviral therapy are ineligible.",{"count":81,"type":20},2000,"Background:\n\n\\- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it.\n\nObjective:\n\n\\- To collect tissue samples for use in the study of lung cancers.\n\nEligibility:\n\n\\- Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cell cancer, pulmonary neuroendocrine tumors, and thymic epithelial tumors.\n\nDesign:\n\n* Participants will be screened with a medical history, physical exam, and blood tests. They will be asked about how they perform their daily tasks.\n* Participants may be asked to give urine and blood samples. They may give a saliva sample if they cannot give blood. They will also give a sample of their tumor from a biopsy they had. They may also be given the option to undergo a biopsy.\n* Participants may have MRI, CT, and\u002For PET scans of the body. They will lie in a machine that takes pictures of the body.\n* After visits to the Clinical Center end, researchers will contact participants by phone every year to check on their health.",[84,25,85,86,87],"Non-Small Cell Lung Cancer","Extrapulmonary Small Cell Cancer","Pulmonary Neuroendocrine Tumors","Thymic Epithelial Tumors",[89,90,91,92,93,94],"Sample Acquisition","Genetic and Epigenetic Alterations","Mig6 Expression","Proteomic Analysis","Genomic Analysis","Natural History","2026-06-27",{"date":62,"type":31},{"date":98,"type":31},"2014-05-28",{"date":100,"type":20},"2029-12-31",{"name":102,"class":103},"National Cancer Institute (NCI)","NIH",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":114,"type":20},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,25,137,138,139,140,141,142],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-06-26",{"date":145,"type":31},"2026-06-29",{"date":147,"type":31},"2025-09-18",{"date":149,"type":20},"2028-03-30",{"name":151,"class":71},"AstraZeneca",17,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":50,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100593337","phase-3-a-study-comparing-tarlatamab-durvalumab-carboplatin-and-etoposide-versus-durvalumab-carboplatin-and-etoposide-in-first-line-extensive-stage-small-cell-lung-cancer-es-sclc-100593337","NCT07005128","A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)","DeLLphi-312","Inclusion Criteria:\n\n* Participant has provided informed consent before initiation of any study-specific activities\u002Fprocedures.\n* Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.\n* Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC \\[T any, N any, M1 a\u002Fb\u002Fc\\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor\u002Fnodal volume that is too large to be encompassed in a tolerable radiation plan.\n* Measurable disease as defined per RECIST 1.1.\n* Suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment per investigator clinical assessment.\n* Minimum life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n* Participants can have no history of other malignancy in the last 2 years.\n* Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.\n* They will have no history of severe or life-threatening events to immune-mediated therapy.\n* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.\n* They will have no active autoimmune or inflammatory disorders.\n* Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B\u002FC) infection.\n* Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.\n* History of solid organ transplant.\n* They will not have had a myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association \\> class II) within 6 months prior to first dose of study treatment.","99 Years",{"count":163,"type":20},330,[165],"PHASE3","The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).",[168,169],"Small-cell Lung Cancer","Extensive Stage Small-cell Lung Cancer","2026-06-24",{"date":172,"type":31},"2026-06-25",{"date":174,"type":31},"2025-08-18",{"date":176,"type":20},"2029-07-15",{"name":178,"class":71},"Amgen",164,{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":16,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":50,"phases":190,"briefSummary":192,"conditions":193,"keywords":216,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":252},"100407463","phase-1-the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle-100407463","NCT04585750","The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","A Phase 1\u002F2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","Inclusion Criteria:\n\n* At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.\n* Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation\n* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Previously treated with one or more lines of anticancer therapy and progressive disease\n* Adequate organ function\n* Measurable disease per RECIST v1.1 (Phase 2)\n\nAdditional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Anti-PD-1\u002FPD-L1 naive or must have progressed on treatment\n* Measurable disease\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug\n* Radiotherapy within 14 days of receiving the study drug\n* Primary CNS tumor\n* History of leptomeningeal disease or spinal cord compression\n* Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms\n* Stroke or transient ischemic attack within 6 months prior to screening\n* Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities\n* Strong CYP3A4 inducers and strong CYP2C9 inhibitors\u002Finducers within 14 days of first dose of rezatapopt\n* History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication\n* History of prior organ transplant\n* Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n* Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n\nAdditional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)\n\n* Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)\n\nAdditional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)\n* Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug\n* Hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* History of radiation pneumonitis\n* History of (non-infectious) or active pneumonitis \u002F interstitial lung disease that required steroids\n* Active infection requiring systemic therapy\n* Known history of HIV infection\n* Has previously received rezatapopt","12 Years",{"count":189,"type":20},300,[191,52],"PHASE1","The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.",[194,195,196,197,198,131,121,133,199,200,201,202,125,123,25,203,204,205,206,56,207,208,209,210,84,211,212,213,214,215],"Advanced Solid Tumor","Advanced Malignant Neoplasm","Metastatic Cancer","Metastatic Solid Tumor","Lung Cancer","Colorectal Cancer","Breast Cancer","Other Cancer","Locally Advanced","Small Cell Lung Cancer ( SCLC )","Small Cell Lung Carcinoma","NSCLC","NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Carcinoma","Triple Negative Breast Cancer","TNBC","HER2+ Breast Cancer","ER\u002FPR Positive Breast Cancer","HER2- Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","ER\u002FPR(+), Her2(-) Breast Cancer",[217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244],"PC14586","p53","Y220C","Phase 1","Phase 1\u002F2","PMV","PMV Pharma","p53 mutation","TP53","TP53 mutation","p53 mutant","p53 reactivator","pembrolizumab","Keytruda","combination","PD-1","PD-L1","anti-PD-1","Merck","MSD","IgG4","mAb","Phase 1b","NGS","Next Generation Sequencing","precision","Phase 2","Rezatapopt",{"date":143,"type":31},{"date":247,"type":31},"2020-10-29",{"date":249,"type":20},"2027-12-31",{"name":251,"class":71},"PMV Pharmaceuticals, Inc",77,{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":50,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":39},"100377838","phase-1-petct-imaging-of-small-cell-lung-cancer-using-89zr-dfo-sc1656-100377838","NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56","Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody","Inclusion Criteria:\n\nSubject Inclusion Criteria for Adult population\n\n* Signed, informed consent\n* Age 18 or more years\n* Histologically confirmed, SCLC, (newly diagnosed or recurrent); small cell carcinoma of unknown or non-lung origin; or other types of neuroendocrine tumor OR Histologically confirmed prostate cancer, with suspected or confirmed NEPC based upon clinical assays obtained prior to the trial OR Histologically confirmed or suspected primary brain neoplasm OR Desmoplastic small round cell tumors, osteosarcoma, Ewing's sarcoma, rabdomyosarcoma, Wilms tumors, hepatoblastomas, rhabdoid tumors and neuroblastoma patients\n* At least one tumor lesion on CT2 or MRI ≥ 0.8 cm OR\n* Tumor detectable FDG PET, PSMA PET, DOTATATE PET, MIBG SPECT (or planar MIBG scan if SPECT unavailable) OR\n* MRI or bone scan that shows new osseous metastases. The scans should have been obtained in the last 12 weeks\n* ECOG performance status 0 to 2\n* Negative serum pregnancy test within 2 weeks of 89Zr-DFO-SC16.56 for women of child-bearing potential\n* Available archival tumor specimen suitable for DLL3 IHC or clinician already has plans to obtain tumor specimen as part of standard of care (unrelated to patient participation in 19-292) which will yield sufficient tumor specimen to allow for DLL3 IHC\n* For the prostate cancer patient cohort, as an alternative if archival tissue is not available, patients must be willing to undergo PET\u002FCT guided biopsy3 as described in section 9.3.\n\n  1. Patients with SCLC will be the primary study population, however patients with other types of neuroendocrine tumors may be included at the PI's discretion.\n  2. Criterion is intended to demonstrate presence of imageable disease. A low-dose CT (e.g. from a PET\u002FCT scan) may be used at PI's discretion.\n  3. While willingness to undergo the biopsy is required if archival tissue is not available, PET\u002FCT guided biopsy is not a mandatory study assessment. As described in section 9.3, the guided biopsy may be waived at the discretion of the principal investigator if the DLL3 PET\u002FCT reveals no sites of DLL3 tracer-avid tumor or if the principal investigator deems itis not in the best interest of the patient, according to best clinical judgement. The pediatric population would not be approached for an optional PET\u002FCT-guided biopsy\n\nSubject Inclusion Criteria for Pediatric population\n\n* Signed, informed consent\n* Age 4 or more years\n* High risk neuroblastoma patients\n* At least one tumor lesion on CT2 or MRI ≥ 0.8 cm OR Tumor detectable FDG PET, PSMA PET, DOTATATE PET, MIBG SPECT (or planar MIBG scan if SPECT unavailable) OR MRI or bone scan that shows new osseous metastases. The scans should have been obtained in the last 12 weeks\n* ECOG performance status 0 to 2\n* Performance Status: Subjects must have a Lansky (\\\u003C16 years) of at least 40\n* Negative serum pregnancy test within 2 weeks of 89Zr-DFO-SC16.56 for women of child-bearing potential\n\nExclusion Criteria:\n\nSubject Exclusion Criteria for the Adult population\n\n* History of anaphylactic reaction to humanized or human antibodies\n* Pregnant or breast feeding\n* Psychiatric illness that would interfere with compliance with the study procedures\n* Inability to undergo PET scan due to weight limit\n* Patients who require anesthesia or monitored sedation to tolerate PET scan procedure\n\nSubject Exclusion Criteria for the Pediatric population\n\n* History of anaphylactic reaction to humanized or human antibodies\n* Pregnant or breast feeding\n* Psychiatric illness that would interfere with compliance with the study procedures\n* Inability to undergo PET scan due to weight limit\n* Patients who require anesthesia or monitored sedation to tolerate PET scan procedure",{"count":261,"type":20},53,[191,52],"The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.",[25,204],[266,204,267,268,269],"Small cell lung cancer","89Zr-DFO-SC16.56","19-292","Memorial Sloan Kettering Cancer Center",{"date":172,"type":31},{"date":272,"type":31},"2019-12-11",{"date":274,"type":20},"2027-06-11",{"name":269,"class":38},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":4},"100644636","epigenomic-profiling-of-circulating-cell-free-dna-cfdna-to-characterize-the-dynamic-evolution-of-molecular-subtypes-in-extensive-stage-small-cell-lung-cancer-during-first-line-chemoimmunotherapy-100644636","NCT07670442","Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy","Profilage épigénomique de l'ADN Circulant Libre (cfDNA) Pour caractériser l'évolution Dynamique Des Sous-types moléculaires du Cancer du Poumon à Petites Cellules à un Stade étendu au Cours de la chimiothérapie-immunothérapie de première Ligne","EPICIRC-SCLC","Inclusion Criteria:\n\nHistologically or cytologically confirmed SCLC\n\nIndication for first-line systemic anti-tumor treatment with chemo-immunotherapy as decided in a multidisciplinary tumor board.\n\nPatient's ability to comply with the required study follow-up.\n\nAge ≥ 18 years.\n\nPatient affiliated with a social security scheme.\n\nPatient managed in the Thoracic Oncology department of Cochin Hospital or HEGP.\n\nPatient able to understand the participant information sheet.\n\nExclusion Criteria:\n\nExpressed refusal at the time of receiving the information sheet.\n\nPerson not proficient in the French language.\n\nPerson deprived of liberty or under legal protection (including guardianship or curatorship).\n\nPregnancy or breastfeeding.",{"count":285,"type":20},50,"The EPICIRC SCLC project aims to improve our understanding and treatment of extensive-stage small cell lung cancer (ES SCLC), the most aggressive form of lung cancer that accounts for 15% of all cases. Despite current treatments, which combine chemotherapy with immunotherapy, the outlook for patients remains poor, with an average survival of just 12 months. Recent research has shown that this cancer can be classified into four subtypes, which respond differently to anti-cancer treatments. However, these subtypes may change over time, particularly during chemotherapy, which could explain why many patients eventually become resistant to treatment. Understanding how these subtypes evolve could pave the way for better treatment strategies, but it has been difficult to study these changes because new tumor samples are rarely collected after a patient is diagnosed. The EPICIRC SCLC project tackles this challenge by using liquid biopsies, a minimally invasive technique that analyzes circulating free DNA (cfDNA) found in patients blood. This approach allows to monitor changes in the tumor's molecular profile over time without needing additional tissue samples. By collecting and analyzing blood samples from patients at three key points-before treatment, after four cycles of chemo-immunotherapy, and at disease progression-the project aims to track the evolution of the tumor's molecular subtypes and identify patterns associated with treatment resistance. Using advanced epigenomic technologies, we will study how genes are regulated and how their activity changes during treatment. This will provide a detailed map of the tumor's molecular evolution and could uncover new targets for future therapies. In the long term, these findings would lead to more personalized treatment strategies, helping clinicians select therapies based on the specific molecular profile of each patient's cancer at different stages of their treatment.",[25],[289,290,291],"liquid biopsy","cell free DNA","Smal Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-19",{"date":143,"type":31},{"date":296,"type":20},"2026-07-01",{"date":298,"type":20},"2030-07-01",{"name":300,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":50,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100609712","phase-3-a-study-of-zl-1310-versus-investigators-choice-of-therapy-in-participants-with-relapsed-small-cell-lung-cancer-dllevate-100609712","NCT07218146","A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer","DLLEVATE","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years, or considered an adult by local regulations, at the time of consent\n* Signed informed consent\n* Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed.\n* Measurable disease according to RECIST v1.1 as assessed by the investigator.\n* Participants with a history of treated and stable or untreated and asymptomatic CNS metastases based on criteria per protocol.\n* Adequate organ and marrow function\n* Eastern Cooperative Group (ECOG) performance status of 0 or 1\n* Life expectancy of at least 3 months\n* Participants must be willing to undergo a tumor biopsy or provide archived tumor tissue sample at Screening\n* Participants must be willing and able to comply with protocol for the duration of the study\n\nExclusion Criteria:\n\n* Received more than one line of systemic therapy for Extensive-Stage SCLC.\n* Received any prior ADC with topoisomerase 1 inhibitor payload\n* Participants with another known malignancy with exceptions defined in the protocol.\n* History or suspected ILD\u002Fpneumonitis based on criteria per protocol\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.\n* Receipt of anti-cancer treatment known to treat cancers within 3 weeks before the first dose of study treatment.\n* Prior radiotherapy before study treatment based on criteria per protocol\n* Unresolved toxicity of Grade \\>\u002F= 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation.\n* Known infection or active infection defined in the protocol.\n* Clinically significant active cardiovascular disease or history of arterial thromboembolic event within 6 months prior to the first dose of study treatment based on criteria per protocol.",{"count":310,"type":20},480,[165],"The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.",[168],"2026-06-18",{"date":316,"type":31},"2026-06-23",{"date":318,"type":31},"2025-11-30",{"date":320,"type":20},"2028-11-30",{"name":322,"class":71},"Zai Lab (Shanghai) Co., Ltd.",66,{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":50,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":39},"100608993","phase-1-a-study-of-yl201-and-ivonescimab-ak112-in-advanced-solid-tumors-100608993","NCT07208773","A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","A Multi-center, Open-label, Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.\n3. ECOG PS score is 0 or 1.\n4. Within 7 days before the first dose, the functions of body organs and bone marrow meet the requirements.\n\nExclusion Criteria:\n\n1. Suitable for local curative treatment.\n2. Have received previous treatment with drugs targeting B7-H3 (including antibodies, ADCs, CAR-T, and other drugs).\n3. Have received previous treatment with topoisomerase I inhibitors or ADCs containing topoisomerase I inhibitors.\n4. Have experienced grade ≥ 3 irAEs during previous treatment with anti-programmed death receptor (ligand) \\[anti-PD-(L)1\\] or other immune checkpoint inhibitors.\n5. History of bleeding tendency or coagulation disorders and\u002For clinically significant bleeding symptoms or risks within 4 weeks before randomization.\n6. Imaging studies during the screening period show that the patient has the Imaging-confirmed tumor invasion of major blood vessels.\n7. Active autoimmune disease requiring systemic treatment.\n8. Brain metastases or spinal cord compression.\n9. Patients with uncontrolled or clinically significant cardiovascular diseases.\n10. Clinically significant concurrent pulmonary diseases.\n11. Known to have active pulmonary tuberculosis. Other protocol-defined inclusion\u002F exclusion criteria may apply",{"count":332,"type":20},260,[191,52],"This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.",[336,337,25],"Advanced Solid Tumors","Non Small Cell Lung Cancer",[339,340,341,337,25],"Advanced solid tumors","PD1\u002FVEGF Bispecific","Antibody drug conjugate","2026-06-17",{"date":314,"type":31},{"date":345,"type":31},"2025-10-29",{"date":347,"type":20},"2027-12",{"name":349,"class":71},"MediLink Therapeutics (Suzhou) Co., Ltd.",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":50,"phases":359,"briefSummary":360,"conditions":361,"keywords":364,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":39},"100632066","phase-1-68ga-pfd3-pet-imaging-for-the-diagnosis-and-evaluation-of-small-cell-lung-cancer-100632066","NCT07508852","68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer","Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET\u002FCT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Adults.\n* Histologically confirmed small cell lung cancer (SCLC).\n* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.\n* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Breastfeeding.\n* Acute psychiatric disorders.\n* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).\n* Inability to complete the study procedures as anticipated.\n* Prior therapy targeting DLL3.",{"count":358,"type":20},30,[191,52],"This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).",[56,362,363,25,203],"SCLC, Extensive Stage","SCLC, Limited Stage",[56,365,366,367,368,369,370,371,372],"small cell lung cancer","PET\u002FCT","PET","DLL3","Delta-like ligand 3","imaging","diagnosis","evaluation","2026-06-16",{"date":314,"type":31},{"date":376,"type":31},"2025-10-22",{"date":249,"type":20},{"name":379,"class":38},"Peking University First Hospital",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":50,"phases":389,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":405},"100589661","a-study-of-hospital-at-home-for-people-receiving-tarlatamab-100589661","NCT06957314","A Study of Hospital-at-Home for People Receiving Tarlatamab","MATCHES-Novel: MAking Telehealth Delivery of Cancer Care at Home Effective and Safe for Novel Therapies: A Hospital-at-Home Model for Tarlatamab Delivery","Inclusion Criteria:\n\nPatient\n\n* Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)\n* Treatment plan of commercially available tarlatamab monotherapy as standard of care\n* Patients must be 18 years of age or older\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2\n* Patients must have adequate organ and bone marrow function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:\n\n  * ANC ≥ 1000 cells\u002FμL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)\n  * Platelet count ≥50,000\u002FμL (without transfusion within 4 weeks prior to Cycle 1, Day 1)\n  * Hemoglobin ≥8.0 g\u002FdL (without transfusion within 4 weeks prior to Cycle 1, Day 1)\n  * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3 X upper limit of normal (ULN). Serum bilirubin ≤ 1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level ≤ 2 x ULN may be enrolled.\n  * Estimated Glomerular Filtration Rate (eGFR) ≥ 30mL\u002Fmin using the CKD-EPI formula.\n* The patient is willing to give and sign informed consent\n* Appropriate homebound setting as defined by one of the following:\n\n  * Lodging at MSK Residence or hotel\n  * 5 New York City boroughs, lower Westchester County (northern boundary Cross County Parkway) and Nassau County (eastern boundary Wantagh State Parkway). This is based on the community paramedic (SeniorCare) 60-minute response time catchment area. If there is any uncertainty about patient residence eligibility, the Principal Investigator will decide after discussion with SeniorCare.\n* Patients must be accompanied by a caregiver for the period of time the patient is enrolled in the HaH intervention. For cases where there is uncertainty, the Principal Investigator will make the final determination.\n\nCaregiver\n\n* Primary caregiver as identified by patient enrolled on study\n\nPhysician\n\n* Treating physician for patient(s) enrolled on study; managing treatment plan of commercially available tarlatamab as standard of care\n\nExclusion Criteria:\n\nPatient\n\n* Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.\n* Patients with baseline dementia or cognitive barriers\n* Uncontrolled arrhythmias\n\nCaregiver\n\n* Caregiver deemed inappropriate by treating physician\n\nPhysician\n\n* No exclusion criteria",{"count":388,"type":20},70,[390],"NA","The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).",[168,204],[168,204,394,269,395,396],"Tarlatamab","25-077","extensive stage small cell lung cancer","2026-06-11",{"date":399,"type":31},"2026-06-12",{"date":401,"type":31},"2025-04-23",{"date":403,"type":20},"2028-04-23",{"name":269,"class":38},7,{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":50,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":39},"100524051","locally-ablative-therapy-for-oligoprogressive-lung-and-thoracic-malignancies-obliterate-100524051","NCT06103682","LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)","OBLITERATE","Inclusion Criteria:\n\n1. Must have one of the following histologically and\u002For biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Non-small cell cancer\n   2. Cohort B: Small cell cancer\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age ≥18 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. ≤ 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\u002F interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.",{"count":114,"type":20},[390],"This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.",[417,418,168],"Non-small Cell Lung Cancer","Oligoprogressive",{"date":420,"type":31},"2026-06-15",{"date":422,"type":31},"2023-10-05",{"date":424,"type":20},"2032-01-05",{"name":426,"class":38},"University of California, Davis",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":436,"studyType":21,"phases":4,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100459048","tempus-small-cell-lung-cancer-observational-study-sculptor-100459048","NCT05257551","Tempus Small Cell Lung Cancer Observational Study (Sculptor)","Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays","The following are the inclusion criteria. Participants are eligible to be included in this study only if all the following criteria apply. The participant has\u002Fis:\n\n1. Histologically confirmed small cell lung cancer diagnosis\n2. Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the Medical Monitor)\n3. Subjects must submit tumor sample per the laboratory manual, defined as follows: 1L Cohort - Tissue obtained prior to the initiation of 1L therapy; 2L Cohort - Tissue obtained prior to the initiation of 1L therapy and\u002For a standard of care re-biopsy prior to the start of 2L therapy, if performed.\n4. ECOG performance status of 0-2 at time of enrollment\n5. For participants entering prior to first line therapy, planned extensive stage first-line therapy of etoposide plus platinum plus PD-L1 inhibitor (atezolizumab or durvalumab)\n6. For participants entering post completion of standard of care first line prior to second line therapy, completion of an EP+CPI with or without maintenance therapy. Note: Participants who received 1L therapy that is not standard of care i.e., investigational therapy, are not eligible.\n7. Extensive stage disease at time of diagnosis according to NCCN definition: Extensive Stage Small Cell Lung Cancer (SCLC) as either Stage IV disease (any T, any N, with M1a\u002Fb\u002Fc) or T3-4 disease due to multiple lung nodules that are too extensive or have a tumor\u002Fnodal volume that is too large to be encompassed in a tolerable radiation plan (NCCN version 2.2026-September 16, 2025).\n8. Willing and able to provide informed consent\n9. Palliative radiotherapy is permitted as long as there is measurable disease outside of the radiotherapy port with which to assess response to therapy delivered\n\nParticipants will be excluded from the study if any of the following criteria apply. The participant has\u002Fis:\n\n1. Patients with a secondary malignancy must have been both diagnosed \\> 3 years from the lung cancer of interest and have completed all therapy for that malignancy \\> 3 years prior to diagnosis of the lung cancer of interest, with the exception of the following:\n\n   1. Patients with superficial basal cell carcinoma of low-risk histology per NCCN Guidelines (Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus) and low-risk for recurrence per NCCN Guidelines (location on trunk or extremities, size \\\u003C 2 cm, primary (not recurrent), with well-defined borders) can be included even if they are diagnosed \\\u003C 3 years from the lung cancer of interest.\n   2. Patients with superficial squamous cell carcinoma of low-risk pathology per NCCN Guidelines (verrucous, keratoacanthomatous) and low-risk for recurrence per NCCN Guidelines (located on trunk or extremities; ≤ 2 cm in size; primary lesion (vs. recurrent); well to moderately differentiated; \\\u003C 2 mm thick and no invasion beyond subcutaneous fat; negative for perineural invasion; and negative for lymphatic or vascular involvement) can be included even if they are diagnosed \\\u003C 3 years from the lung cancer of interest.\n2. Mixed small cell and non-small cell histology\n3. Small cell cancers of origin in other organs or suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)\n4. Large Cell Neuroendocrine cancers\n5. Carcinoids or atypical carcinoid tumors\n6. Transformed small cell lung cancer emerging in the setting of targeted therapy for NSCLC\n7. Treated with an investigational agent of another immunotherapy class (i.e., non PD-1 or PD-L1 inhibitor)\n8. Not willing to have additional blood samples collected",{"count":435,"type":20},200,"3 Years","The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.",[25],[440,441,442,443,444,56,25,240,445,446,447,448],"Cancer","Oncology","Observational","Genomic Profiling","Precision medicine","Biomarkers","ctDNA","Transcriptomics","Extensive Stage",{"date":420,"type":31},{"date":451,"type":31},"2022-07-13",{"date":453,"type":20},"2029-03",{"name":455,"class":71},"Tempus AI",11,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":50,"phases":466,"briefSummary":467,"conditions":468,"keywords":472,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":405},"100471453","phase-2-a-study-of-stereotactic-radiosurgery-srs-for-people-with-lung-cancer-that-has-spread-to-the-brain-100471453","NCT05419076","A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain","A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Histologic diagnosis of small cell lung cancer\n* Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI\n* Age 18 and above\n* Performance status KPS 60-100\u002FECOG 0-2\n* Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment\n* The patient or legally authorized representative is able to provide informed consent\n\nExclusion Criteria:\n\n* Unable to undergo contrast-enhanced MRI brain\n* Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine\n* Pregnant or lactating women\n* Prior brain-directed radiotherapy\n* Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET\u002FCT imaging, no more than 3 months before study enrollment",{"count":465,"type":20},62,[52],"The purpose of the study is to see if stereotactic radiosurgery\u002FSRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer\u002FSCLC.",[198,469,470,471,168,204],"Lung Cancer Metastatic","Brain Metastases","Brain Metastases, Adult",[473,365,474,475,476,477,478,269],"Stereotactic Radiosurgery","small cell lung carcinoma","lung cancer","lung cancer metastatic","brain metastases","22-133","2026-06-09",{"date":481,"type":31},"2026-06-10",{"date":483,"type":31},"2022-06-10",{"date":485,"type":20},"2027-06-10",{"name":269,"class":38},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":50,"phases":496,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":4},"100643763","phase-2-ql1706-plus-anlotinib-as-a-later-line-treatment-for-patients-with-advanced-lung-cancer-100643763","NCT07636226","QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","A Multicenter, Open-label, Randomized Controlled Phase II\u002FIII Study Evaluating the Efficacy and Safety of QL1706 in Combination With Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","Inclusion Criteria:\n\n* 1\\. Male or female patients aged 18 years and above, up to 80 years old. 2. Small cell lung cancer or lung squamous cell carcinoma confirmed by tissue or pathological examination.\n\n  3\\. Requires previous treatment with platinum-based drugs. 4. Requires previous treatment with PD-1\u002FPD-L1 drugs. 5. Patients must have received at least 2 lines of treatment, no more than 3 lines of treatment.\n\n  6\\. Confirmed as small cell lung cancer by histological examination. 7. Able to provide informed consent and comply with the trial protocol. 8. According to RECIST 1.1 standards, there are measurable lesions (CT scan). 9. Expected lifespan ≥ 12 weeks. 10. ECOG performance status 0-1. 11. Patients must have adequate organ and bone marrow functions, defined as follows:\n  1. Absolute neutrophil count ≥ 1,500\u002FmcL\n  2. Platelet count \\> 90,000\u002FmcL\n  3. Hemoglobin ≥ 9 g\u002FdL (allowing for Hgb transfusion)\n  4. Creatinine ≤ 1.5 × ULN\n  5. Total bilirubin ≤ 1.5 mg\u002FdL or ≤ 26 μmol\u002FL\n  6. If there is liver metastasis, AST (SGOT) \u002F ALT (SGPT) ≤ 5 × ULN; if there is no liver metastasis, ≤ 2.5 × ULN\n  7. Albumin ≥ 2.5 g\u002FdL 12. Patients are allowed to receive palliative radiotherapy (such as radiotherapy after brain metastasis), provided that there are measurable target lesions in the radiation field of the patient.\n\n     13\\. Able to go to the research center to ensure that patients complete all research-related appointments.\n\n     14\\. Pregnant women and male partners of pregnant women must agree to take adequate contraceptive measures (hormonal or barrier methods; abstinence) before entering the study, during the study, and within 90 days after completing the study (hormonal or barrier methods; abstinence). If a woman becomes pregnant during the study or suspects she is pregnant, she should immediately inform the attending doctor.\n\n     Note: Pregnant women are defined as any woman meeting the following criteria (regardless of sexual orientation, whether tubal ligation has been performed or being single):\n\n  \u003C!-- -->\n\n  1. No hysterectomy or bilateral oophorectomy;\n  2. No natural menopause for at least 12 consecutive months (i.e., any time during the previous 12 months there was menstruation).\n\n     Exclusion Criteria:\n* 1\\. Patients with symptomatic central nervous system metastases, or those with unstable neurological symptoms requiring an increase in the dosage of corticosteroids.\n\n  2\\. Presence of another primary malignant tumor (excluding cervical carcinoma in situ or skin basal cell carcinoma).\n\n  3\\. The patient has a clinically significant disease that affects their participation in this study, including but not limited to: active or uncontrolled infection, SARS-CoV-2 infection, immunodeficiency, hepatitis B, hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled arrhythmia, QTc interval prolongation \\> 450 ms or a mental illness\u002Fsocioeconomic condition that limits their compliance with the study requirements.\n\n  4\\. Previous use of CTLA-4 monotherapy or combination antibodies containing CTLA-4.\n\n  5\\. Previous treatment with anti-angiogenic drugs. 6. Presence of uncontrolled or symptomatic pleural or pericardial effusion, etc.\n\n  7\\. Uncontrolled or clinically significant third-space effusion. 8. Severe adverse reactions occurred during previous immunotherapy, and the investigator considers it unsuitable for re-administration of immunotherapy.\n\n  9\\. Any condition that may interfere with the subject's participation in the study or the evaluation of the study results.\n\n  10\\. Receiving major surgery within 30 days before the first day of the study. 11. Currently using or expected to use within 14 days before the first administration of drugs or foods known to be potent CYP3A4\u002F5 inhibitors or CYP3A4\u002F5 inducers (such as grapefruit juice or grapefruit\u002Fgrapefruit-related citrus fruits (such as oranges, grapefruits), ketoconazole, miconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquanavir, ritonavir, nelfinavir, amprenavir, fosamprenavir, nefazodone, lopinavir, ritonavir), and applying these drugs locally (such as 2% ketoconazole cream is allowed);","80 Years",{"count":5,"type":20},[52,165],"This is a multicenter, open-label, randomized controlled phase II\u002FIII study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.",[25],[365,500],"later-line","2026-06-04",{"date":479,"type":31},{"date":504,"type":20},"2026-07-30",{"date":506,"type":20},"2029-12-30",{"name":508,"class":38},"Sun Yat-sen University",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":50,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":39},"100575379","phase-2-association-of-thoraco-mediastinal-radiotherapy-with-maintenance-immunotherapy-treatment-with-atezolizumab-100575379","NCT06771518","Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab","Lung Microcytoma Extensive Disease: Prospective Study of Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab","Inclusion Criteria:\n\n* Histological diagnosis of lung microcytoma;\n* Age ≥18 years;\n* Performance status according to ECOG 0-2;\n* Extended disease at the time of first line oncological treatment;\n* Initial staging and restaging after chemo-immunotherapy with CT, CT-PET FDG and brain MRI;\n* In at least partial response (defined according to the Recist criteria \\[18\\]) after treatment chemoimmunotherapy according to the Impower 133 scheme;\n* Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy;\n* Pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: FEV≥1.2 l or \\>40%, DLCO≥50%;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Previous radiotherapy treatment at the thoraco-mediastinal level;\n* In disease progression after chemo-immunotherapy treatment.",{"count":517,"type":20},37,[52],"Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.",[25],{"date":522,"type":31},"2026-06-05",{"date":524,"type":31},"2021-12-15",{"date":526,"type":20},"2026-12-15",{"name":528,"class":38},"Regina Elena Cancer Institute",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":50,"phases":538,"briefSummary":539,"conditions":540,"keywords":545,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":554},"100629562","phase-2-symbiotic-lung-14-a-study-to-learn-about-the-study-medicine-called-pf08634404-in-combination-with-chemotherapy-in-adult-participants-with-transformed-small-cell-lung-cancer-100629562","NCT07476287","Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of informed consent.\n* Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).\n* Participants have not received systemic therapy for T-SCLC.\n* Have at least one measurable lesion as the target lesion based on RECIST v1.1.\n* Have sufficient tumor tissue from the diagnosis of transformed SCLC available.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Have a minimum life expectancy of \\>12 weeks.\n* Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter \\\u003C1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.\n* Leptomeningeal disease\n* Clinically significant risk of hemorrhage or fistula, including tumor necrosis\u002Fcavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula\n* History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)\n* Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)\n* History of allogeneic organ or hematopoietic stem cell transplantation\n* Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)\n* Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:\n\n  * Prior or current non-infectious pneumonitis requiring systemic therapy\n  * DLCO \\\u003C50% predicted\n  * Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement\n* Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose\n* Baseline QTcF \\>480 msec\n* Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study\n* Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage\n* History of significant bleeding disorders or recent major bleeding events\n* Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding\n* Active, uncontrolled, or symptomatic infection, including:\n\n  * Active TB\n  * Active hepatitis B or C\n  * Uncontrolled HIV infection\n* History of immunodeficiency\n* Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies\n* Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation\n* Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods\n* Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes\n* Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)\n* Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements",{"count":537,"type":20},40,[52],"This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.\n\nTo join the study, participants must meet the following conditions:\n\n* Are aged 18 years or older\n* Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)\n* Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)\n* Have healthy organs based on medical tests and are in good physical condition\n\nAfter joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.",[25,203,541,542,543,544],"Transformed Small Cell Lung Cancer","Lung Neoplasms","Carcinoma, Small Cell Lung","Small Cell Cancer Of The Lung",[541,25],"2026-06-03",{"date":501,"type":31},{"date":549,"type":20},"2026-05-15",{"date":551,"type":20},"2031-03-19",{"name":553,"class":71},"Pfizer",12,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":50,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":358},"100523424","phase-2-a-study-of-alisertib-in-patients-with-extensive-stage-small-cell-lung-cancer-100523424","NCT06095505","A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","ALISCA-Lung1","Inclusion Criteria:\n\n* Aged ≥18 years at signing of informed consent\n* Pathologically confirmed SCLC\n* Prior treatment with one platinum-based chemotherapy and an anti-PD-L1\u002FPD-1 immunotherapy. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens\n\nExclusion Criteria:\n\n* Prior treatment with an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting\n\nNote: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.",{"count":5,"type":20},[52],"PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1\u002FPD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.",[25],[568,56],"Alisertib",{"date":522,"type":31},{"date":571,"type":31},"2024-02-08",{"date":573,"type":20},"2028-04-30",{"name":575,"class":71},"Puma Biotechnology, Inc.",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":4},"100628977","sclc-tarlatamab-blood-collection-100628977","NCT07468656","SCLC Tarlatamab Blood Collection","Analysis of Blood Samples in Small Cell Lung Cancer Patients Treated With Tarlatamab","Inclusion Criteria:\n\n* Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor\n* Appropriate candidate for treatment with tarlatamab based on investigator discretion\n* Age \\> 18 years\n* Signed written informed consent including HIPAA according to institutional guidelines\n\nExclusion Criteria:\n\n* Does not meet all inclusion criteria",{"count":7,"type":20},"The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.\n\nThe investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.",[168],"2026-06-02",{"date":546,"type":31},{"date":589,"type":20},"2026-07",{"date":591,"type":20},"2028-12",{"name":593,"class":38},"Duke University",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":50,"phases":604,"briefSummary":605,"conditions":606,"keywords":612,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":4},"100639777","phase-1-a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors-100639777","NCT07623369","A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors","An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 in Patients With Advanced Solid Tumors","Key Inclusion Criteria\n\n1. Adults aged 18 to 75 years with signed informed consent.\n2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.\n3. At least 1 measurable lesion per RECIST v1.1.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks.\n5. Adequate organ function based on protocol-specified laboratory criteria.\n\nKey Exclusion Criteria\n\n1. Active leptomeningeal disease or uncontrolled\u002Funtreated brain metastases.\n2. History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components.\n3. Other malignancy within 3 years prior to first dose, except specified curatively treated cancers.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.\n5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage\u002Fhemoptysis.\n\nNOTE: Other eligibility criteria may apply.","75 Years",{"count":603,"type":20},56,[191],"This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.",[607,417,608,199,609,134,121,120,168,208,610,611],"Solid Tumor","Hepatocellular Carcinoma","Head and Neck Squamous Cell Carcinoma","Urothelial Carcinoma","Gastroesophageal Adenocarcinoma",[613,614,417,205,608,615,199,616,617,609,134,618,121,120,168,208,209,610,611,131],"HH160","PD-1×CTLA-4×VEGF-A Antibody","HCC","CRC","GEA","RCC","2026-05-29",{"date":546,"type":31},{"date":622,"type":20},"2026-06",{"date":624,"type":20},"2028-08",{"name":626,"class":71},"Huahui Health",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":50,"phases":637,"briefSummary":638,"conditions":639,"keywords":640,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":650},"100531700","phase-3-a-study-of-ifinatamab-deruxtecan-versus-treatment-of-physicians-choice-in-subjects-with-relapsed-small-cell-lung-cancer-100531700","NCT06203210","A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)","IDeate-Lung02","Inclusion Criteria\n\nParticipants must meet all the following criteria to be eligible for randomization into the study:\n\n1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures.\n2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.\n3. Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).\n4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content.\n5. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval of ≥30 days.\n6. Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the investigator.\n7. Has documentation of radiological disease progression on or after the most recent systemic therapy.\n8. Has ECOG PS of ≤1 within 7 days prior to Cycle 1 Day 1 (C1D1).\n9. Has no evidence of brain or leptomeningeal disease (spinal cord or central nervous system \\[CNS\\] metastases) based on history and physical examination. Subjects must require no treatment with steroids or anticonvulsants and have a stable neurologic status for at least 2 weeks prior to the first dose of study drug.\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.\n2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.\n3. Has received any of the comparators used in this study or any topoisomerase I inhibitor.\n4. Has inadequate washout period before randomization as specified in the protocol.\n5. Has any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.\n6. Has uncontrolled or significant cardiovascular disease.\n7. Has clinically significant corneal disease.\n8. Has any history of ILD\u002Fpneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.\n\n   Examples of suspected ILD\u002Fpneumonitis by imaging include the presence of lung parenchymal fibrosis, such as combined pulmonary fibrosis and emphysema (CPFE) and any radiographic features consistent with ILA, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing.\n9. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen.",{"count":636,"type":20},540,[165],"This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).",[25],[266,641,642],"Ifinatamab deruxtecan","I-DXd",{"date":586,"type":31},{"date":645,"type":31},"2024-05-21",{"date":647,"type":20},"2029-02-22",{"name":649,"class":71},"Daiichi Sankyo",232,{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":50,"phases":660,"briefSummary":661,"conditions":662,"keywords":668,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":672,"completionDateStruct":673,"leadSponsor":675,"locationsCount":4},"100638863","phase-3-evaluate-bl-m14d1-plus-atezolizumab-vs-standard-of-care-in-first-line-extensive-stage-small-cell-lung-cancer-100638863","NCT07625644","Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer","A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)\n* Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.\n* At least one measurable lesion based on RECIST v1.1 per investigator assessment.\n* An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.\n* Participants who have received prior topoisomerase inhibitor-based ADC therapy.\n* Participants with history of severe heart disease\n* Participants with active autoimmune diseases and inflammatory diseases,\n* Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and\u002For carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":659,"type":20},550,[165],"The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).",[663,168,664,665,666,198,469,667],"Small Cell Lung Cancer Extensive Stage","Small Cell Carcinoma","Sclc","SCLC,Extensive Stage","Lung Cancer Stage IV",[368,669],"First Line","2026-05-28",{"date":501,"type":31},{"date":622,"type":20},{"date":674,"type":20},"2031-06",{"name":676,"class":71},"SystImmune Inc.",{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":683,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":685,"targetDuration":4,"studyType":50,"phases":687,"briefSummary":688,"conditions":689,"keywords":690,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":704},"100633777","phase-1-study-of-tarlatamab--zl-1310---anti-programmed-death-ligand-1-anti-pd-l1-in-small-cell-lung-cancer-sclc-100633777","NCT07531095","Study of Tarlatamab + ZL-1310 +\u002F- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)","A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer","DeLLphi-313","Inclusion Criteria:\n\n* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.\n* Participants with Histologically or cytologically confirmed SCLC:\n* For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.\n* For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowed in Cohort 2-1.\n* For Part 3, participants must have extensive-stage SCLC (ES-SCLC) with no prior systemic treatment other than 1 cycle of platinum-based chemotherapy.\n\nNote: Participants with prior treatment for limited-stage SCLC (LS-SCLC) before diagnosis of ES SCLC are permitted.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* At least 1 measurable lesion as defined per RECIST v1.1 within 21-day screening period, not previously irradiated.\n* Adequate organ function (hematological, coagulation, renal, hepatic, pulmonary, and cardiac function).\n\nExclusion Criteria:\n\n* Symptomatic CNS metastases. Participants with treated brain metastases are eligible provided they meet the criteria specified in the protocol.\n* History of interstitial lung disease (ILD)\u002Fpneumonitis.\n* Received thoracic radiation therapy within 90 days prior to first dose of trial intervention.\n* Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy.\n* Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.\n* Receiving strong CYP3A4 or CPY2D6 inhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose of trial treatment.\n* Enrollment in any tarlatamab clinical trial.",{"count":686,"type":20},160,[191],"The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and\u002For recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.",[25],[394,691,692,56,693,694,695,696],"ZL-1310","Durvalumab","Anti-PD-L1","Extensive Stage Small Cell Lung Cancer","Programmed death protein-1 (PD-1)","Programmed death ligand 1 (PD-L1)","2026-05-27",{"date":619,"type":31},{"date":700,"type":31},"2026-04-21",{"date":702,"type":20},"2031-05-21",{"name":178,"class":71},6,{"id":706,"slug":707,"hasResults":12,"nctId":708,"briefTitle":709,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":601,"enrollmentInfo":712,"targetDuration":4,"studyType":50,"phases":713,"briefSummary":714,"conditions":715,"keywords":4,"overallStatus":292,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":716,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":721,"locationsCount":39},"100635995","phase-1-a-study-of-dxc006-with-immune-checkpoint-inhibitors-or-platinum-for-small-cell-lung-cancer-100635995","NCT07559929","A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","A Phase Ib\u002FII Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.","Inclusion Criteria:\n\n1. Voluntarily signed informed consent and willingness to comply with the protocol requirements.\n2. Male or female.\n3. Age ≥18 years and ≤75 years.\n4. Life expectancy ≥3 months.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n6. Histologically or cytologically confirmed small cell lung cancer (SCLC).\n7. Toxicity from prior anti-tumor therapy has resolved to ≤ Grade 1 as defined by NCI-CTCAE version 6.0 (except alopecia); peripheral neuropathy must have completely resolved.\n8. Adequate hepatic, renal, coagulation, and cardiac function.\n9. The participant and their spouse agree to use effective barrier or pharmacologic contraception (excluding rhythm method) from the time of signing the informed consent until 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed combined SCLC, NSCLC, sarcomatoid carcinoma, or large cell neuroendocrine carcinoma.\n2. Within 14 days prior to the first dose: underwent plasmapheresis; received systemic corticosteroid therapy at a daily dose \\>10 mg prednisone or equivalent (or equivalent anti-inflammatory activity) for more than 3 consecutive days (short-term use for prevention of contrast media allergy is permitted).\n3. Prior allogeneic hematopoietic stem cell transplantation (HSCT) or history of solid organ transplantation.\n4. Prior treatment with CD56-targeted therapy.\n5. Symptomatic brain metastases or leptomeningeal metastases.\n6. History of severe or life-threatening immune-related adverse events or infusion-related reactions (including permanent discontinuation of immuno-oncology therapy due to intolerance).\n7. Active autoimmune disease or immunodeficiency, or a history of such conditions.\n8. Evidence of significant cardiovascular risk.\n9. Dyspnea or current requirement for continuous supplemental oxygen therapy, or current active pneumonitis or interstitial lung disease (except mild cases as determined by the investigator).\n10. History of other primary malignancies, with the exception of malignancies that have been cured and have a very low risk of recurrence within 5 years, such as basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.\n11. Severe non-healing wound, ulcer, or bone fracture; or major surgery within 28 days prior to dosing, or anticipated major surgery during the study period.\n12. History of hypersensitivity to any component or excipient of DXC006, immune checkpoint inhibitors, or platinum-based chemotherapy.\n13. Active hepatitis B (HBV-DNA above the upper limit of normal at the central laboratory or \\>1000 copies\u002FmL); hepatitis C infection (positive hepatitis C antibody or positive HCV RNA PCR result).\n14. Known positive serology for human immunodeficiency virus (HIV); active syphilis (patients with positive syphilis antibody only are eligible); potential active pulmonary tuberculosis (chest imaging within 3 months prior to the first dose suggestive of active tuberculosis infection).\n15. Active bleeding within 30 days prior to screening, or risk of major gastrointestinal bleeding or hemoptysis as determined by the investigator; or hereditary bleeding tendency, coagulopathy, or bleeding symptoms requiring other medical intervention.\n16. Severe arterial or venous thromboembolic events within 6 months prior to study drug administration, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism.\n17. Positive serum pregnancy test or currently breastfeeding female participants.\n18. Active infection requiring medical therapy (CTCAE Grade ≥2); uncontrollable pleural effusion, ascites, or pericardial effusion requiring repeated drainage.\n19. Administration of live attenuated vaccines within 28 days prior to the first dose.\n20. Other conditions that, in the judgment of the investigator, may affect the patient's participation in the study.\n21. Poor general condition, such as requirement for mechanical ventilation and\u002For intravenous catecholamine infusion, and\u002For severe neurological impairment, coma, and\u002For quadriplegia with complete loss of communication ability (deafness, blindness, aphasia); uncontrolled seizures; other psychiatric disorders that may affect study participation.",{"count":435,"type":20},[191,52],"This is a Phase Ib\u002FII, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).",[25],{"date":619,"type":31},{"date":718,"type":20},"2026-06-01",{"date":720,"type":20},"2030-12-30",{"name":722,"class":71},"Hangzhou DAC Biotechnology Co., Ltd."]